Clinical trials: Early Alzheimers Disease
Neurodegenerative Disorders, Parkinson Disease
An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's Dementia, Frontotemporal…
- Conditions
- Neurodegenerative Disorders, Parkinson Disease, Alzheimer Disease, Parkinsonian Disorders
- Trial name
- SANDY (NCT06875739)
- Where
- 4 sites in Italy
- Volunteers
- 310 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
As the population increases and aging intensifies, cognitive disorders represented by Alzheimer's disease (AD) not only pose a severe threat to public health but also bring significant social and economic burdens.
- Trial name
- NCT06741553
- Testing
- Lecanemab 10 mg/kg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Alzheimer Disease, Mild Cognitive Impairment
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders
- Trial name
- NCT05364307
- Testing
- Prescreener database
- Where
- 19 sites in United States, Canada
- Volunteers
- 1,555 people
- Sponsor
- Global Alzheimer's Platform Foundation
Alzheimer Disease, Early Onset, Alzheimer Disease
A Safety Study of PTI-125 in Healthy Volunteers
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
- Trial name
- NCT03784300
- Testing
- 50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Mild Cognitive Impairment, Alzheimer Disease
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment…
- Trial name
- STAND (NCT04522739)
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 3
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
- Trial name
- ADNI3 (NCT02854033)
- Where
- 59 sites in United States, Canada
- Volunteers
- 1,141 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Mild Cognitive Impairment, Alzheimer Disease
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center.
- Trial name
- BVB (NCT03136679)
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Parkinson Disease, Alzheimer Disease
Effectiveness of Probiotic K10 in Managing Health Outcomes in Parkinson and Alzheimer Disease
Evaluation of the effects of the K10 probiotic mix in patients with degenerative neurological diseases (Parkinson and Alzheimer's) with a focus on cognitive, motor and psychiatric neurological evaluation.
- Trial name
- Probiótico (NCT06019117)
- Testing
- Probiotic K10
- Where
- Brazil
- Volunteers
- 104 people
- Sponsor
- Deivis de Oliveira guimaraes
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Alzheimer's Disease, Mild Cognitive Impairment
FluoroAv45 Imaging Research-in Alzheimer's Disease
Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a major matter of concern. There is now an important body of literature stating that early isolated cognitive deficits (Mild Cognitive…
- Trial name
- FAIR-AD (NCT01325259)
- Testing
- neuropsychologic assessment, [18F]AV-45 PET, 18-FDG PET
- Where
- 4 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Alzheimers Disease
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
- Trial name
- TRAVELLER (NCT07177352)
- Testing
- No Intervention
- Where
- 234 sites in United States, Argentina and 13 more
- Volunteers
- 80,000 people
- Sponsor
- Hoffmann-La Roche
Early Alzheimer's Disease
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.
- Trial name
- NCT05161715
- Testing
- Obicetrapib
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- NewAmsterdam Pharma
Mild Cognitive Impairment, Alzheimer Disease
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- NCT07041450
- Testing
- Digital MoCA, XpressO, MoCA
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- MoCA Clinic and Institute
Alzheimer Disease
Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers
The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild…
- Trial name
- CBTAC (NCT01273272)
- Testing
- Comprehensive, CBT-based, multi-component treatment, Treatment as usual
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Alzheimer Disease, Alzheimer Disease, Early Onset
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies.
- Trial name
- TMSLA (NCT07036328)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Willem de Haan
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Mindfulness for Cognition in Early-stage Alzheimer's Disease
The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging
- Trial name
- NCT06792877
- Testing
- Mindfulness Intervention, Waitlist then mindfulness
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Boston Healthcare System
Alzheimer Disease, Alzheimer' Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment…
- Trial name
- NCT06885567
- Testing
- BEY2153
- Where
- 3 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- BeyondBio Inc.
Alzheimer Disease
Tau Screening Study in Subjects With Early Symptomatic AD
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron…
- Trial name
- NCT03467477
- Testing
- Flortaucipir F18, Brain PET Scan
- Where
- 9 sites in United States
- Volunteers
- 161 people
- Sponsor
- Avid Radiopharmaceuticals
Dementia, Alzheimers Disease
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
This study is collecting tissue specimens (blood, urine and saliva) from up to 1000 patients, with and without cognitive disorders, to store in the Bio Bank for future research.
- Trial name
- NCT00911690
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Corewell Health East
Alzheimer Disease, Lymphatic Obstruction
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
The objective of this investigational device exemption (IDE) study is to evaluate the safety and feasibility of using the Symani System and microsurgical techniques in the deep cervical lymph node (dCLN) region in the setting of…
- Trial name
- REMIND (NCT07178210)
- Testing
- Symani Surgical System
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- MMI (Medical Microinstruments, Inc.)